Jabbour, Elias
Short, Nicholas J.
Jain, Nitin
Haddad, Fadi G.
Welch, Mary Alma
Ravandi, Farhad
Kantarjian, Hagop
Article History
Received: 23 September 2022
Accepted: 9 February 2023
First Online: 16 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: EJ received research grants from Abbvie, adaptive biotechnologies, Amgen, Pfizer, and Takeda; and consultancy fees from Abbvie, adaptive biotechnologies, Amgen, BMS, Genentech, Incyte, Novartis, Pfizer, and Takeda. NJS received research grants from Takeda Oncology, Astellas Pharma Inc., Xencor and Stemline Therapeutics; consultancy fees from Pfizer Inc. and Jazz Pharmaceuticals; and honoraria from Novartis, Amgen, Sanofi, and BeiGene. HK received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision Biosciences, Taiho Pharmaceutical Canada. FGH, MAW, NJ, and FR declare no competing interests.